Shanghai Wibson Biotechnology (revision 39)
Old revision·22:33, 4 Aug 2025·TallySheetTad
| Shanghai Wibson Biotechnology Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Shanghai Wibson Biotechnology Co., Ltd. |
| Trading name | SWB |
| Other designations | SWB Biotech, Shanghai Wibson Biotechnology |
| Identity | |
| Founded | 2019 |
| Headquarters | Shanghai, China |
| Industry | Research-compound supply |
| Shop domain | Visit SWB |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| PeptidePedia reception tally | |
| Submissions | 915 to July 2026 |
| Evidence quality | Weak — self-selected, self-reported |
| Organisation infobox · conventions | |
Shanghai Wibson Biotechnology Co., Ltd. (trading as SWB; shanghaiwibsonbiotechnology.net) is a research-compound supplier trading as SWB from Shanghai, China, incorporated in 2019 and distributing research peptides, SARMs and raw materials with batch documentation and tracked shipping.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2019, the organisation is among the more recently established covered on this wiki, and its operating record is correspondingly shorter.[1] A short history is not a defect and is not treated as one here; it does mean that observations about consistency rest on fewer years of reports than for the older entities.
Its registered name places it in biotechnology, which is closer to its trading activity than several comparable registrations.[1] Beyond the registry record and its own material, the documentary base for this article is thin, and the notability discussion on the talk page turns on exactly that.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Purchaser reports describe conventional practice: lyophilised material in crimped glass vials, batch certificate enclosed, cold pack for the temperature-sensitive lines.[5] Certificates in submitted material have typically reported a purity figure and an appearance line without a water content, so the reported purity cannot be converted into a net mass.[6]
No certification claim by the organisation has been corroborated by this wiki, and its own statements about capability are self-published.[2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide | Certificate, purity only |
| Research peptides | Repair and secretagogue peptides | Certificate, purity only |
| SARMs | Bulk and capsuled | Certificate, variable |
| Injectable oils and raw materials | Bulk | Certificate, limited detail |
The catalogue is broadly the sector standard and does not distinguish the organisation from its comparators, which is itself a relevant fact for a reader trying to tell them apart.[2]
Independent testing record
[edit]Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported area percent figures have clustered in the high nineties.[5]
The absence of water figures on the accompanying certificates is the substantive documentation gap in this set: a purity figure alone constrains the relative composition of what dissolved and says nothing about how much peptide the vial held.[6] As elsewhere, samples were purchaser-selected rather than blind-drawn, so the reports cannot be read as a sample of output.[5]
Reception
[edit]The PeptidePedia tally records 915 self-reported submissions to July 2026. Recurring positive themes are responsiveness and delivery times; recurring complaints concern certificate depth.[4] Self-selected sample; reception rather than quality.[4]
See also
- Certificate of analysis
- Third-party testing
- Area percent purity
- Peptide content
- Research use only
- Peptide supply chain
References
- ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ a b c PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.